Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 · New England Journal of Medicine · 5,033 citations
https://doi.org/10.1056/nejmoa033025
Y
Yves Humblet
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
281
Papers
25.9K
Citations
50
h-index
116
i10-index
Yves Humblet is an academic researcher. The author has contributed to research in topics: Colorectal Cancer Treatments and Studies & Lung Cancer Treatments and Mutations & Cancer Treatment and Pharmacology. The author has an h-index of 50, co-authored 239 publications.
Papers by this author
worksEvolution of Metastases in Space and Time under Immune Selection
2018 · Cell · 452 citations
https://doi.org/10.1016/j.cell.2018.09.018
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
2007 · British Journal of Cancer · 85 citations
https://doi.org/10.1038/sj.bjc.6604053
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone
2015 · British Journal of Cancer · 17 citations
https://doi.org/10.1038/bjc.2015.321
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat